Notice of AGM, Directorate Changes & Annual Report
2 October 2026
Kromek Group plc
(“Kromek” or the “Group”)
Notice of AGM and Publication of Annual Report
Directorate Changes
Update on Bank Facility
Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, gives notice of its Annual General Meeting (“AGM”) and publication of annual report, announces directorate changes and provides an update on its bank facility.
Notice of AGM and publication of annual report
The Group’s AGM will be held at 9.30am on Friday 23 October 2026 in the Kromek ‘Biosecurity’ Boardroom at Explorer 1 Building, North East Technology Park (NETPark), Thomas Wright Way, Sedgefield, County Durham, TS21 3FF.
The notice of AGM and form of proxy, along with the Group’s annual report and accounts for the year ended 30 April 2026, have been published on the ‘Company Documents & Reports’ page in the Investor Relations section of the Group’s website at https://investors.kromek.com/company-documents. The documents are being posted today to those shareholders who have requested paper communications.
Directorate changes
Kromek announces that Chris Wilkes, who has served as Non-Executive Director since 2017, will be retiring from the Board and Jane Pearce will be appointed as a Non-Executive Director of the Company with effect from the conclusion of the AGM. Jane will assume the role of Chair of the Audit Committee.
Jane, who is a qualified chartered accountant, brings significant senior level financial markets experience to the Board. She spent a number of years as a Technology Equity Analyst and as an Equity Strategist at leading investment banks in the City of London, including HSBC, Lehman Brothers and Nomura International. She is currently Chair of Morgan Stanley Investment Management Limited and a Non-executive Director of Morgan Stanley Bank International Limited, Morgan Stanley & Co International plc and Polar Capital Technology Trust, a FTSE 100-listed investment trust where she chairs the Audit Committee.
Update on bank facility
Further to its final results announcement of 14 September 2026, the Group is pleased to confirm that it has finalised an agreement for a £3.0m expansion to its revolving credit facility (“RCF”) with HSBC. The increased RCF facility will be used to support and assist working capital requirements.
Rakesh Sharma, Chairman of Kromek, said: “On behalf of the Board, I would like to express our sincere thanks to Chris for his contribution and guidance over the last nine years, and we wish him well in his future endeavours. I am delighted to welcome Jane to Kromek, who will bring significant financial markets as well as corporate governance experience. I am also pleased to confirm the extension to our RCF with HSBC bank, which will support our working capital and, in particular, our growth in Advanced Imaging.”
Enquiries
|
Investor questions on this announcement |
|
|
We encourage all investors to share questions on this announcement via our investor hub |
|
|
|
|
|
Kromek Group plc |
|
|
Arnab Basu, CEO Claire Burgess, CFO |
+44 (0)1740 626 060 |
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
|
Geoff Nash/Giles Balleny/Seamus Fricker – Corporate Finance Andrew Burdis – ECM Michael Johnson – Sales |
+44 (0)20 7220 0500
|
|
|
|
|
Gracechurch Group (Financial PR) |
|
|
Harry Chathli/Claire Norbury |
+44 (0)20 4582 3500 |
Engage with the Kromek management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our interactive investor hub here: https://investors.kromek.com/
Subscribe to our news alert service: https://investors.kromek.com/auth/signup
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.
The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.
Regulatory Disclosures:
The following information regarding the appointment of Jane Osmani-Pearce (née Pearce), aged 58 is disclosed under Schedule 2(g) of the AIM Rules for Companies:
|
Current directorships: |
Morgan Stanley Investment Management Morgan Stanley &Co International Ltd Morgan Stanley &co International plc Morgan Stanley Bank International Ltd Polar Capital Technology Trust plc 37 Kempsford Garden Residents ltd |
|
|
|
|
Historic directorships and partnerships in previous 5 years: |
Shires Income plc Audit and Risk Committee of St Andrews University |
Jane was a director of Shires Income plc when it was dissolved in March 2026 under a section 110 liquidation and rollover into an existing vehicle (Aberdeen Equity Income), with no outstanding amounts due to creditors.
Jane holds no shares or share options in Kromek.
There are no further disclosures required under Schedule 2(g) of the AIM Rules for Companies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE